Sunnsailor has been in the sun faaaaaar toooooo long. Your one man pumping operation isn't working very well for JADA. Anc watch who you call a chump..#$%$!
When do we get to hear something from the company instead of your unintelligible dribble?
Does your incessant whining ever stop? You have mentioned that you hold 33,000 shares at approximately a $3 average. Too #$%$ing bad! Your whining has nothing to do with company outcomes. It may take a year, but the turnaround has already started. Have some #$%$ing faith in the stock that YOU bought and shut your #$%$ ing mouth. Your BS is tiresome in Ihub as well!
Has anyone else thought that it might have made much more sense for Navidea to do the Crede offering AFTER releasing these two PRs from the past few days and thus getting a much better price than 2.11 per share? I still maintain that by pricing the company at 2.11, considerable damage was needlessly done to market cap and retail investors. The company should have timed the offering after the RIGS and 5001 news we have just had. Now it seems as if the market could care less. I try not to imagine how high the pps might have surged on these two recent PRs if the offering and poor sales had not happened...
would the morons at Navidea understand how mad longs are at this mess?
What Are the Shorts Really Up To?
What we know—
Outstanding shares are approx.. 94 million (about 145 million fully diluted). Short interest is about 10.8 million (11% of outstanding; 13% of float)
Avg volume is 322,000. Cash on hand is about $30 million. Cash burn is $6.5 million per quarter.
Lymphoseek PDUFA is June 10. The chances of approval are high due to excellent safety profile, drug is quicker, more effective, will be only FDA approved product allowing insurance companies to pay for it, Lymphoseek finds cancer that current drug leaves undetected. There is a small possibility the approval could come earlier.
Lymphoseek will be sold by Cardinal Health, the largest radiopharmaceutical distributor in the US which will ramp up sales quickly after approval.
Lymphoseek will be approved in Europe and ROW. Lymphoseek has been tested with breast cancer and melanoma. Head and neck cancer trial is underway. Lymphoseek could potentially be used for other solid tumors.
RIGS, a $2 billlion drug, will enter clinical testing late 2012.
AZD4694 (“Amyloseek”), an amyloid imaging agent, has been licensed by the company and will be in Phase III testing.
Altropane, a Parkinson’s disease imaging agent, has been optioned.
NEOP reached a high of $5.48 June 1, 2011. Soon after it was viciously attacked by a lying #$%$ Marty Shrek, a known stock manipulator. He and others took the stock down to a low of $1.62 in early Aug, 2011.
Open interest in the following options is notable: April, 12 $3, $4,and $5 calls is 5,000 plus for each. Jan,13 $3 is 26,000, $5 is 10,000.
My point in rehashing all the above is to examine the question “What in the hell are the shorts doing?”
Theory #1 is that the shorts are idiots. The bullish case for NAVB has been laid out in tremendous detail. If you don’t want to read DDbuyer’s material, look at one of the 8 or 9 analysts who all are recommending “Buy”. Is the huge short position simply a BIG mistake?
Theory #2 is that at some point in the past shorting may have made sense, but now the shorts are “stuck” in this thinly traded stock with no way to get out. There didn’t seem to be a lot of shorting under $3, but when the stock ran over $3, Shrek blew his dog whistle, and the shorting is apparent. Friday afternoon, after trading 120K shares all day, at 3:40 pm the volume picked up dramatically. A 100K shares traded in 20 minutes with the stock eeking out a small gain. The short volume that day was just under 70%. In other words, the shorts fought hard to prevent a last minute run-up in the price.
Theory #3 is that NAVB is fully or over-valued at $3.
Theory #4 is that shorting small biotechs is simply something bigshots can do because they have so much power. The companies are small and vulnerable, and it’s just a profitable thing to do.
I don’t know the answer to this, but I’m concerned we are missing something.
by shorts INSTEAD of the shorts covering and taking their gains? Do they really think this is headed under 1.00 and that the stock is their's to drive lower at will?
1.4 million shares traded again today and we lost 7 more cents. The shorts strategy is unclear, especially considering the December 5th conference coming up in NYC.
FIRST management gets the GE line of credit in late June 2013 as a smoke screen to make the company appear cash strong - even though the terms of this financing are so poor that additional financing will be necessary within a few short months.
SECOND management makes the Crede deal look like Crede paid 2.84 per share. In reality, Crede paid the equivalent of 2.11 per share and PROBABLY SOLD all 10,000,000 shares for a gain on the way down to 2.11.
This gave the shorts momentum to drive the pps even lower when...
THIRD management releases exceptionally poor sales despite having said only a few weeks earlier that sales were looking great.
FOURTH within two days of poor sales for Q3, the pps hits an unimaginably low 1.11 and 7 million shares trade over two days. Even the insiders finally buy shares that they refused to buy since March when Lymphoseek was approved. The pps decline from the 2.84 official Crede price to 1.11 is a decline of 60.9%.
Companies with an FDA denial do not always decline this much and NAVB did not have an FDA denial.
FIFTH if European Approval comes by the end of November, the pps could rebound and then millions and millions of shares that were essentially stolen from longs who sold or were forced to sell over the past 30 days are in new hands.
SIXTH management is also planning a save the date meeting in NYC for December 5th. The better the news is at this event, the less necessary the orchestrated decline in pps by management was.
MANAGEMENT WORKED ALL OF THIS OUT TO THE BENEFIT OF THE SHORTS. LET THE SEC INVESTIGATION BEGIN.
My eyes are on Cheshire, Connecticut. I wish the torture that occurred there in 2007 on the families of Larson, Pykett, and the rest of those at Navidea that sold shareholders up the river! Look us the case. :)